AVITA Medical Inc

AVITA Medical, Inc. through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product RECELL system is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company is headquartered in Valencia, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AVITA Medical Inc reports robust Q4 earnings and growth outlook

AVITA Medical's strong financial performance in Q4 2022 and full year 2022, coupled with strategic initiatives and growth projections for 2023, position the company for continued success.
While facing challenges in managing expenses and achieving regulatory approvals, AVITA Medical's focus on innovation, market expansion, and operational efficiency presents opportunities for sustained growth.
Investors should monitor the company's progress in securing PMA approvals, expanding market presence, and optimizing operational costs to capitalize on the projected revenue growth and market opportunities.

AVITA Medical reports robust Q1 earnings, eyes FDA approvals

AVITA Medical Inc. delivered strong financial results in Q1 2023, driven by revenue growth and operational improvements.
The company's strategic priorities for 2023 are on track, with pending FDA applications and new product launches in the pipeline.
While facing challenges in operational transitions and market competition, AVITA Medical remains focused on innovation and growth.

AVITA Medical reports strong Q2 performance with FDA milestones

AVITA Medical had a strong quarter with revenue growth and landmark FDA approvals.
The company faces challenges with increased expenses and supply chain issues.
Opportunities lie in market expansion, new FDA approvals, and international growth strategies.
AVITA Medical aims for realistic growth, focusing on hitting guidance targets to build credibility.

AVITA Medical reports robust revenue growth and strategic international expansion

AVITA Medical Inc's Q3 2023 performance reflects strong revenue growth and strategic initiatives to drive international expansion and profitability by 2025.
The company's focus on core business areas, confidence in growth prospects, and commitment to enhancing patient outcomes position it well for future success.
While facing challenges in pricing strategies and global expansion pace, AVITA Medical is poised to capitalize on opportunities in wound care innovation, regulatory approvals, and international market expansion.

AVITA Medical reports strong earnings, eyes global expansion and profitability

AVITA Medical Inc showcased robust financial performance and strategic advancements in Q4 2023 earnings call.
While facing challenges such as net losses and restructuring, the company is well-positioned for growth.
Opportunities lie in product launches, global expansion, and operational efficiency improvements.
Overall, AVITA Medical's performance and outlook signal a promising trajectory for future success.

AVITA Medical Inc reports Q1 revenue miss, eyes profitability by 2025

AVITA Medical Inc faced challenges in Q1 2024 with revenue falling short of expectations, but the company remains focused on strategic initiatives to drive growth and expand its product portfolio. Despite challenges, AVITA is optimistic about its international expansion efforts and aims to achieve profitability by the third quarter of 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

VALENCIA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fiscal first quarter of 2021, ended September 30, 2020.

AVITA Therapeutics Reports First Quarter 2021 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, is pleased to announce the results of its 2020 Annual Meeting of Shareholders that was held virtually today, being Monday, November 9, 2020 (Valencia, California) / Tuesday, November 10, 2020 (Melbourne, Australia).

AVITA Therapeutics, Inc.: Results of 2020 Annual Meeting of Shareholders

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that David McIntyre notified the Company of his intention to resign as the Company's Chief Financial Officer in order to pursue life sciences opportunities in his home state of New Jersey. The effective date of his resignation is November 23, 2020. Mr. McIntyre has also agreed to provide consultancy services to the Company through December 31, 2020 so as to support a smooth transition of his responsibilities. The Company wishes to thank David for successfully leading and completing the redomiciliation project during his tenure as well as for his many valuable contributions to AVITA's executive leadership team.

AVITA Therapeutics, Inc. Announces Executive Change

VALENCIA, Calif, and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announces today a correction in the time for the adjourned 2020 Annual Stockholder Meeting (“Adjourned Annual Meeting”), due to the change in daylight savings time Pacific Time in the United States, it results in change in time in Australian Eastern Daylight Time (AEDT) from 7:00 am to 8:00 am on Tuesday, November 10, 2020 and remains unchanged at 1:00 pm Pacific Time on Monday, November 9, 2020.   

Avita Therapeutics, Inc. Announces Correction of Time for the Adjourned 2020 Annual Stockholder Meeting

VALENCIA, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has changed the date and time of its previously announced earnings release and conference call for first quarter 2021. The Company will now announce results one day earlier on Tuesday, November 10, 2020. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time (being 8:30am Australian Eastern Daylight Time on Wednesday, November 11) to discuss its financial results and recent highlights.

AVITA Therapeutics Announces Date Change for First Quarter 2021 Earnings Release and Conference Call

VALENCIA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, wishes to advise that its 2020 Annual Stockholder Meeting (the “Annual Meeting”), which was scheduled to be held today, October 29, 2020 at 1.00 p.m. Pacific Time (being Friday, October 30, 2020 at 7.00 a.m. Australian Eastern Daylight Time (“AEDT”)), was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

AVITA Therapeutics, Inc. Announces Adjournment of 2020 Annual Stockholder Meeting

VALENCIA, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will participate in the following upcoming investor conferences.

AVITA Therapeutics to Participate in Upcoming Investor Conferences

VALENCIA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its first quarter 2021 financial results after the market closes on Wednesday, November 11, 2020. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and recent highlights.

AVITA Therapeutics to Announce First Quarter 2021 Financial Results

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc.

AVITA Therapeutics to Participate at the Canaccord Genuity 40th Annual Growth Conference

Chemed

These modern healthcare stocks could take care of you very well.

2 Stocks  That Offer Explosive Potential Gains

Spectacular performer in 2019 still has a long way to go.

Avita Medical Enters 2020 With Great Momentum

Baidu

Zillow

Today's risky stocks could be tomorrow's blockbuster investments.

3 High-Risk, High-Reward Stocks for Your Watch List

ArQule

Axsome Therapeutics

Constellation Pharmaceuticals Inc

DURECT

EverBank Financial

IVERIC bio Inc

Kodiak Sciences Inc

Provention Bio Inc

Stage Stores

These Were the 10 Best Stocks of 2019

Avadel Pharma

New Oriental Education & Technology Group

Sibanye-Stillwater

Vipshop Hlds

Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.

5 Top-Ranked ADRs That More Than Doubled the S&P 500 in 2019

News for AVITA Medical Inc Stock (RCEL)